STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network.

doi:10.1016/j.jid.2017.07.839

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network.

The Journal of investigative dermatology - 1 Jan 2018

Delyon Julie, Chevret Sylvie, Jouary Thomas, Dalac Sophie, Dalle Stephane, Guillot Bernard, Arnault Jean-Philippe, Avril Marie-Françoise, Bedane Christophe, Bens Guido, Pham-Ledard Anne, Mansard Sandrine, Grange Florent, Machet Laurent, Meyer Nicolas, Legoupil Delphine, Saiag Philippe, Idir Zakia, Renault Victor, Deleuze Jean-François, Hindie Elif, Battistella Maxime, Dumaz Nicolas, Mourah Samia, Lebbe Celeste

Abstract excerpt

Mutated oncogenic KIT is a therapeutic target in melanoma. We conducted a multicenter phase II trial on the KIT inhibitor nilotinib in patients with unresectable melanoma harboring KIT alteration. The primary endpoint was the response rate (complete response or partial response following Response Evaluation Criteria in Solid Tumors criteria) at 6 months. Pharmacodynamic studies using KIT sequencing, qPCR array,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents

Share to Melanoma

Share to Phosphorylation

Share to Proto-Oncogene Proteins c-kit

Share to Pyrimidines

Share to Skin Neoplasms

Share to STAT3 Transcription Factor

Source

Open in PubMed

Identifiers

PMID: 28843487
DOI: 10.1016/j.jid.2017.07.839

Genes

KIT
STAT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network.PMID 28843487Read ↗

Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06).Semantic proximity Read ↗

Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.Semantic proximity Read ↗

Nilotinib in patients with metastatic melanoma harboring KIT gene aberration.Semantic proximity Read ↗

JAK-ing up the Response to KIT Inhibition.Semantic proximity Read ↗

A potential role for nilotinib in KIT-mutated melanoma.Semantic proximity Read ↗

Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma.Semantic proximity Read ↗

Functional and sensitivity profiling of the <i>KIT</i> Mutation Landscape in MelanomaSemantic proximity Read ↗

C-Kit non-mutated metastatic melanoma showing positive response to Nilotinib.Semantic proximity Read ↗

Clinical and genomic correlates of imatinib response in melanomas with KIT alterations.Semantic proximity Read ↗

A screen for combination therapies in <i>BRAF/NRAS</i> wild type melanoma identifies nilotinib plus MEK inhibitor as a synergistic combinationSemantic proximity Read ↗

Imatinib targeting of KIT-mutant oncoprotein in melanoma.Semantic proximity Read ↗

c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.